Casirivimab+imdevimab

Casirivimab+imdevimab belongs to the group of monoclonal antibodies used in the post-exposure treatment of mild to moderate respiratory illness caused by COVID-19 in people aged 12 years or older, weighing at least 40kgs. Casirivimab+imdevimab is used in non-hospitalised cases of COVID-19 that are at risk of progressing to severe disease.

Casirivimab+imdevimab works by inducing an antibody response in the body by instilling monoclonal antibodies that mimic the natural defences of the body and block the spike protein of the virus from attaching to body cells, thus arresting the progression of the disease.

Advanced age, obesity, chronic kidney disease, lung disease, sickle cell disease, neurodevelopmental disorders (for example cerebral palsy) and diseases of metabolism are high-risk factors for disease progression.

Not enough literature exists to ascertain the effects of Casirivimab+imdevimab on fertility. Please consult your doctor in case of any concerns.

Covid-19 spreads through respiratory droplets when in close or direct contact with an infected person. The virus can spread through an infected person’s sneeze or cough. The virus can also be transmitted by touching any contaminated surfaces and then touching the nose, mouth or eyes without washing the hands.

Vaccines stimulate the body to make its own antibodies against infection. On the other hand, monoclonal antibodies deliver lab-made antibodies against the virus.

Patients with a high risk of developing COVID-19 disease means, those who have certain underlying medical conditions or factors that make them more likely to experience serious illness if they contract COVID-19. These conditions include advanced age, obesity, chronic kidney disease, lung disease, sickle cell disease, neurodevelopmental disorders (for example cerebral palsy) and diseases of metabolism.

An antibody cocktail is a combination of two or more monoclonal antibodies which are separately available but are mixed together. Hence, the name cocktail.

Before taking Casirivimab+imdevimab, inform your doctor if you are allergic to Casirivimab+imdevimab, if you are using prescription and non-prescription medications, vitamins, nutritional supplements, and herbal products. Also, inform your doctor if you have been vaccinated against COVID-19. Discuss the severity and duration of your COVID-19 symptoms to ensure the treatment is appropriate for your condition and also let your doctor know if you are breastfeeding, pregnancy or planning pregnancy.

Monoclonal antibodies are proteins made in a laboratory meant to stimulate immune system. Casirivimab+imdevimab is a treatment that contains two monoclonal antibodies. These antibodies work together to neutralize the SARS-CoV-2 virus by binding to different parts of the virus's spike protein, preventing it from entering human cells.

Monoclonal antibodies neutralize SARS-CoV-2 by binding to its spike protein, preventing virus entry into human cells and reducing viral load, potentially alleviating symptoms and reducing disease severity.

Monoclonal antibody therapy for COVID-19 should be administered as soon as possible and within 5-7 days of symptom onset. Starting the treatment early in the course of the infection is crucial for it to be effective in reducing the risk of severe illness, hospitalization, and death.

Certain individuals should avoid monoclonal antibody therapy for COVID-19, including those who, are allergic to monoclonal antibody treatment, having severe or critical COVID-19 requiring hospitalization, who are seropositive for SARS-CoV-2 antibodies, indicating previous infection. And inform your doctor if you are breastfeeding, pregnant or planning pregnancy. It's important to discuss your medical history and any concerns with your doctor before starting treatment. They can help determine if monoclonal antibody therapy is safe and appropriate for you.

Casirivimab+imdevimab can be administered either intravenously (into a vein) or subcutaneously (under the skin) by a trained healthcare professional in a hospital. Do not self-administer.

If you have high blood pressure and diabetes, you are recommended to take the advice of your doctor before taking Casirivimab+imdevimab. To avoid potential interactions.

The common side effects of Casirivimab+imdevimab are redness, pain and soreness at the injection site. If any of these side effects persist or worsen, please consult your doctor.